Novo Holdings, established in 1999, is a Danish asset management firm based in Copenhagen. It serves as the investment arm of the Novo Nordisk Foundation, managing its assets and wealth. The company's primary focus is the life science sector, with a diversified portfolio comprising equities, bonds, real estate, infrastructure, and private investments. Novo Holdings maintains a significant influence on Novo Nordisk A/S and Novozymes A/S, ensuring these companies align with the Novo Group's visions and values. It also invests in early and growth-stage life science companies through its venture capital arm, Novo Ventures, which targets investments ranging from USD 5 million to USD 30 million.
Senior Partner and Head of US Principal Investments
Jeffrey Low, MD
Principal, Growth Investments
Heather Ludvigsen
Senior Manager, Venture Investments
Nanna Lüneborg
Principal
Joseph Markson Ph.D
Principal, Venture Investments
Peter Moldt
Partner
Daniel O'Connell
Partner, Venture Investments
Daniel Rasmussen
Principal, Seed Investments
Naveed Siddiqi
Senior Partner, Venture Investments
Eric Snyder
Partner, Venture Investments
Jim Trenkle
Partner, Venture Investments
Past deals in Nordic Europe
Sparrow Quantum
Series A in 2025
Sparrow Quantum Aps. is a Danish company specializing in quantum technology, particularly in the development of advanced light-matter interfaces. The firm focuses on creating deterministic single-photon sources, which are essential for various quantum technologies. Sparrow Quantum boasts the highest efficiency for on-chip single-photon sources globally, characterized by exceptional photon purity, indistinguishability, and outcoupling capabilities. This cutting-edge technology is rooted in over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which the company holds exclusive licenses for key patents. By leveraging self-assembled quantum dots paired with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interactions, providing critical advancements for its clients in the field of photonic quantum technology.
Commit Biologics
Seed Round in 2025
Commit Biologics is a biotechnology research company based in Aarhus, Denmark, founded in 2021. The company focuses on developing a novel immunotherapy platform designed for the treatment of various cancers. This platform utilizes b-specific domain antibodies, which are engineered to effectively target and kill tumor cells. The technology is modular, allowing for customization to engage the body's innate immune response. By activating the complement component of the immune system, Commit Biologics aims to provide innovative treatment options for both cancer and autoimmune diseases.
Antag Therapeutics
Series A in 2024
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.
Stingray Marine Solutions
Acquisition in 2024
Stingray Marine Solutions AS, based in Oslo, Norway, specializes in developing innovative technology for the aquaculture industry, specifically targeting the removal of sea lice from salmon. Founded in 2010, the company provides an optical delousing solution that utilizes camera vision and laser technology to identify and eliminate sea lice without physically handling the fish. This approach improves fish health management by enhancing production while reducing stress on the animals. The technology is rooted in the patented concept of entrepreneur Esben Beck, who transitioned from the oil and gas sector to focus on aquaculture advancements. Stingray Marine Solutions operates as a subsidiary of Beck Engineering AS, emphasizing in-house design, production, software development, and testing to deliver efficient louse removal systems for salmon farmers.
Commit Biologics
Seed Round in 2024
Commit Biologics is a biotechnology research company based in Aarhus, Denmark, founded in 2021. The company focuses on developing a novel immunotherapy platform designed for the treatment of various cancers. This platform utilizes b-specific domain antibodies, which are engineered to effectively target and kill tumor cells. The technology is modular, allowing for customization to engage the body's innate immune response. By activating the complement component of the immune system, Commit Biologics aims to provide innovative treatment options for both cancer and autoimmune diseases.
NMD Pharma
Series B in 2023
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
Acesion Pharma
Series B in 2023
Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.
Chromologics
Seed Round in 2023
Chromologics is a Danish biotechnology company that specializes in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company utilizes a fermentation-derived platform to produce novel, sustainable color pigments. These colorants are designed to be stable across various pH levels and temperatures, making them suitable for a wide range of food applications. By offering a bio-based alternative to traditional colorants like carmine, Chromologics aims to support food producers in creating more natural products while enhancing the color of their offerings.
Hemab
Series B in 2023
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.
Breye Therapeutics
Seed Round in 2022
Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.
Biosyntia
Series B in 2022
Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create tailored biocatalysts at an accelerated pace and efficiency, using a proprietary high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia helps manufacturers reduce production costs and environmental impact compared to traditional chemical synthesis methods. The company operates from the Novo Nordisk Foundation Center for Biosustainability and collaborates with fine chemical manufacturers to promote greener and more sustainable production processes.
NMD Pharma
Venture Round in 2022
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
Hemab
Series A in 2021
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.
Chromologics
Seed Round in 2021
Chromologics is a Danish biotechnology company that specializes in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company utilizes a fermentation-derived platform to produce novel, sustainable color pigments. These colorants are designed to be stable across various pH levels and temperatures, making them suitable for a wide range of food applications. By offering a bio-based alternative to traditional colorants like carmine, Chromologics aims to support food producers in creating more natural products while enhancing the color of their offerings.
The Renewable Energy Partnership
Venture Round in 2021
The Renewable Energy Partnership is a partnership between Novo Holdings, Sampension, and European Energy with the intention to buy land for the construction of solar and wind farms in Denmark and Sweden. The three partners will provide DKK 650 million (approx. EUR 87 million) with the possibility of investments of up to DKK 1.5 billion (approx. EUR 200 million) through debt financing. This will significantly increase investments in the green transition in Denmark and Sweden.
Hemab
Seed Round in 2020
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.
Chromologics
Seed Round in 2020
Chromologics is a Danish biotechnology company that specializes in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company utilizes a fermentation-derived platform to produce novel, sustainable color pigments. These colorants are designed to be stable across various pH levels and temperatures, making them suitable for a wide range of food applications. By offering a bio-based alternative to traditional colorants like carmine, Chromologics aims to support food producers in creating more natural products while enhancing the color of their offerings.
Reapplix
Series A in 2020
Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.
Antag Therapeutics
Venture Round in 2020
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.
Reapplix
Venture Round in 2019
Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.
STipe Therapeutics
Series A in 2019
Stipe Therapeutics, founded in 2018 and based in Aarhus C, Denmark, develops peptide therapeutics aimed at eliminating tumors and cancer. The company focuses on harnessing the innate immune system to combat cancer by creating first-in-class drugs that target intracellular protein-protein interactions within the STING Pathway. This pathway is a crucial driver of innate immunity and plays a significant role in regulating tumorigenesis and autoimmune disorders. Stipe Therapeutics has successfully identified and validated compounds that sensitize the STING pathway, enabling modulation of the tumor microenvironment to promote a robust anti-tumoral response.
Forendo Pharma
Venture Round in 2019
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.
Envirotainer
Private Equity Round in 2018
Envirotainer AB specializes in the production, development, and rental of active temperature-controlled containers designed for the air transportation of temperature-sensitive healthcare products. Established in 1986 and headquartered in Upplands Väsby, Sweden, the company operates internationally with facilities in major locations such as Singapore, Dallas, Frankfurt, and Toronto, along with a network station in Hyderabad. Envirotainer serves a diverse clientele, including pharmaceutical and biotech companies, by offering a comprehensive suite of services that encompasses laboratory testing, qualification, validation support, and training through the Qualified Envirotainer Program. With over 30 years of experience, Envirotainer has established itself as a leader in secure cold chain solutions, ensuring that pharmaceutical products are transported in a controlled environment to meet the demands of the global market.
Forendo Pharma
Venture Round in 2018
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.
Biosyntia
Series A in 2018
Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create tailored biocatalysts at an accelerated pace and efficiency, using a proprietary high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia helps manufacturers reduce production costs and environmental impact compared to traditional chemical synthesis methods. The company operates from the Novo Nordisk Foundation Center for Biosustainability and collaborates with fine chemical manufacturers to promote greener and more sustainable production processes.
NMD Pharma
Series A in 2018
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
Orphazyme
Post in 2017
Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.
Antag Therapeutics
Series A in 2017
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.
Orphazyme
Venture Round in 2017
Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.
Acesion Pharma
Series C in 2016
Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.
Reapplix
Venture Round in 2016
Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.
NMD Pharma
Venture Round in 2016
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
NMD Pharma
Grant in 2016
NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.
Acesion Pharma
Venture Round in 2016
Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.
Biosyntia
Seed Round in 2015
Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create tailored biocatalysts at an accelerated pace and efficiency, using a proprietary high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia helps manufacturers reduce production costs and environmental impact compared to traditional chemical synthesis methods. The company operates from the Novo Nordisk Foundation Center for Biosustainability and collaborates with fine chemical manufacturers to promote greener and more sustainable production processes.
Acesion Pharma
Series B in 2014
Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.
Glionova
Series A in 2014
Glionova AB is a development stage biopharmaceutical company based in Stockholm, Sweden, founded in 2014. The company focuses on developing therapies for challenging cancers, particularly glioblastoma, which is a common and aggressive primary brain tumor. Glionova is advancing its lead product, GLN-1001, an orally bioavailable small molecule designed to induce selective cell death in glioblastoma cells while sparing normal brain tissue. In addition to its research and development efforts, Glionova aims to market its product through strategic partnerships with global pharmaceutical companies that specialize in oncology.
Forendo Pharma
Series A in 2014
Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.
Pulmologix
Venture Round in 2014
Pulmologix AB is a Swedish private clinical stage company founded in 2006 and based in Stockholm. The company focuses on developing, manufacturing, and selling an oral non-steroidal anti-asthmatic drug specifically for the treatment of early onset allergic asthma. Pulmologix is dedicated to exploring innovative medical approaches to address respiratory diseases, contributing to advancements in asthma treatment.
Xellia Pharmaceuticals
Acquisition in 2013
Xellia Pharmaceuticals ApS is a specialty pharmaceutical company headquartered in Copenhagen, Denmark, focused on developing, manufacturing, and supplying anti-infective products for the global market. Established in 1959, the company specializes in both fermented and semi-synthetic active pharmaceutical ingredients (APIs) and finished dosage forms (FDF). Xellia is recognized as a leading supplier of Vancomycin and Colistimethate Sodium, providing clinically effective treatments for serious bacterial and antibiotic-resistant infections as well as certain fungal diseases. The company operates four manufacturing facilities in Hungary, China, and the United States, adhering to current Good Manufacturing Practice (cGMP) standards and regulatory approvals from authorities such as the US Food and Drug Administration. Xellia also offers a range of contract manufacturing services, including custom synthesis for clinical trials and large-scale production, while continually expanding its product range to address evolving treatment needs. With over 850 employees, Xellia serves more than 700 customers across over 70 countries.
Avilex Pharma
Venture Round in 2013
Avilex Pharma Aps is a biotechnology company based in Copenhagen, Denmark, founded in 2012 as a spin-out from the University of Copenhagen. The company was established by Professor Kristian Strømgaard and Associate Professor Anders Bach, focusing on the development of innovative therapies for various neurological conditions. Avilex Pharma specializes in the creation of dimeric peptides that target PSD95 to address neuropathic pain, as well as the development of inhibitors and neuroprotectants aimed at treating ischemic stroke. By leveraging research from the Department of Drug Design and Pharmacology, the company strives to enhance patient recovery and improve treatment outcomes for those affected by these serious medical conditions.
Santaris Pharma
Venture Round in 2012
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.
Chr. Hansen
Post in 2012
Chr. Hansen is a global bioscience company that specializes in developing natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural sectors. Established in 1874, the company focuses on producing cultures, enzymes, probiotics, and natural colors that enhance the flavor, texture, shelf life, and nutritional value of various products, including foods, beverages, dietary supplements, and animal feed. With a strong emphasis on research and development, Chr. Hansen employs over 2,500 individuals across 30 countries and operates main production facilities in Denmark, France, the USA, and Germany. The company's innovative offerings cater to the health and wellness needs of consumers and contribute to sustainable practices in the industry.
Orphazyme
Series A in 2011
Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.
Orphazyme
Seed Round in 2011
Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.
Adenium Biotech
Seed Round in 2011
Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011 and based in Copenhagen. The company specializes in the development and commercialization of antibiotics aimed at treating multi-drug resistant bacterial infections, particularly those acquired in hospital settings. Its primary focus includes complicated urinary tract infections and hospital or ventilator-acquired pneumonia, which are often caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Adenium Biotech's lead product, Arenicin, is a non-hemolytic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against Gram-negative pathogens. The company operates as a semi-virtual biotech entity, supported by a team of experts and an international scientific advisory board, with the goal of advancing the Arenicin program through clinical development and regulatory filing.
Nanoference
Venture Round in 2010
Nanoference ApS develops technology that uses nano particles to deliver Sirna molecules directly to the desired part of the body. The company was founded in 2009 and is based in Aarhus, Denmark.
EpiTherapeutics
Funding Round in 2008
EpiTherapeutics is dedicated to developing innovative cancer therapies through the exploration of epigenetics, a field advanced by Professor Kristian Helin and his team at the Biotech Research & Innovation Centre at the University of Copenhagen. The company focuses on small-molecule therapies, specifically targeting enzymes that regulate transcription in cancerous cells. EpiTherapeutics has established a library of selective small molecule inhibitors aimed at epigenetic regulation, particularly histone demethylases. Its lead pre-clinical compounds are currently being investigated for their potential effectiveness in treating various forms of cancer.
Celltrix
Venture Round in 2006
Celltrix is a Swedish biotechnology/medical device company focusing on reconstructive cosmetic surgery. Research, development and production are based in Malmö. They plan to launch the first product –Credurance – in 2010. Their product represents a new type of dermal filler. An immediate filling effect is achieved and the surrounding cells are presented to a matrix suitable for cell growth. As the cells grow on and inside the matrix, they produce their own environment, natural collagen, which gradually replaces the matrix — biorestoring.
Nuevolution
Series B in 2003
Nuevolution is a small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a patented hybrid technology that combines wet chemistry and molecular biology to accelerate drug discovery. This platform facilitates the rapid synthesis and DNA-tagging of over 1 billion diverse small molecule compounds, allowing for efficient screening and identification of potent drug leads. Nuevolution partners with pharmaceutical and biotechnology companies, having established agreements with major firms such as Merck, GlaxoSmithKline, and Novartis. The company is also involved in a joint venture with EpiTherapeutics and ExpreS2ion Biotechnologies to develop small molecule drugs targeting epigenetic factors, supported by a project budget from the Danish High Technology Fund. Nuevolution focuses on developing treatments for oncology and inflammatory diseases and also provides contract research services, generating revenue from multiple countries, including Denmark, Sweden, and the USA. The company is privately owned by several key Scandinavian investors.
Nuevolution
Series A in 2001
Nuevolution is a small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a patented hybrid technology that combines wet chemistry and molecular biology to accelerate drug discovery. This platform facilitates the rapid synthesis and DNA-tagging of over 1 billion diverse small molecule compounds, allowing for efficient screening and identification of potent drug leads. Nuevolution partners with pharmaceutical and biotechnology companies, having established agreements with major firms such as Merck, GlaxoSmithKline, and Novartis. The company is also involved in a joint venture with EpiTherapeutics and ExpreS2ion Biotechnologies to develop small molecule drugs targeting epigenetic factors, supported by a project budget from the Danish High Technology Fund. Nuevolution focuses on developing treatments for oncology and inflammatory diseases and also provides contract research services, generating revenue from multiple countries, including Denmark, Sweden, and the USA. The company is privately owned by several key Scandinavian investors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.